Emergent BioSolutions (EBS) Capital Expenditures (2010 - 2026)

Emergent BioSolutions' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 60.0% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.5 million (up 133.78% YoY), while the FY2025 annual figure was $1.6 million, down 15.79% from the prior year.
• Capital Expenditures was $2.4 million for Q1 2026 at Emergent BioSolutions, up from -$8.3 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $51.0 million in Q2 2022 to a low of -$82.8 million in Q4 2022.
• Historically, Capital Expenditures has averaged $3.9 million across 5 years, with a median of $2.4 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 4700.0% in 2024, then plunged 2866.67% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$82.8 million in 2022, then soared by 151.21% to $42.4 million in 2023, then slumped by 99.29% to $300000.0 in 2024, then slumped by 2866.67% to -$8.3 million in 2025, then surged by 128.92% to $2.4 million in 2026.
• The last three Capital Expenditures figures came in at $2.4 million (Q1 2026), -$8.3 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.